,8 Although it remains unclear whether CD38 downregulation on tumor cells after mAb treatment is a marker of resistance5,9 or, instead, successful therapy,10 compelling preclinical and clinical data suggest that CD38 surface antigen density before treatment strongly correlates with mAb efficacy.5 Here, CD38 is linked to neoplasm.